Perfil de la empresa · Healthcare

Imeik Technology Development Co

300896 · Shenzhen
Industria
Medical Devices
Bolsa
Shenzhen
País / Región
China
Empleados
1458
Sitio web
www.imeik.net/cn
Precio actual
¥95
En vivo · 5 de octubre de 2026
Compra razonable
≤ ¥64
Entrada con margen de seguridad
Puntuación de crecimiento Baillie
43/100
Floja
Buffett Score
78/100
Sólida
Valor intrínseco · Rango en tres niveles Precio actual ¥95 En vivo · Dentro del rango de valor intrínseco razonable

Rango de valoración compuesto · conservador ¥56–¥64 / razonable ¥90–¥120 / optimista ¥160–¥175. A ¥95, Dentro del rango de valor intrínseco razonable.

Al publicar ¥92.68 (21 de septiembre de 2026)

Resumen financiero
Capitalización28,75 mil M CNY
Ingresos (TTM)2369,18 M CNY
EBITDA1154,28 M CNY
Margen neto46,22 %
ROE13,44 %
PER (TTM)26,17
PER previsto17,76
PEG0,96
BPA3,63 CNY
Rentabilidad por dividendo1,96 %
Rango de 52 semanas82,46 CNY – 178,80 CNY

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

Sobre la empresa

Imeik Technology Development Co.,Ltd. engages in the research and development, and transformation of biomedical materials and biopharmaceutical products in China. The company offers aesthetic medicine products, such as cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere; poly facial implant thread; medical sodium hyaluronate-hydroxypropyl methylcellulose gel; sodium hyaluronate composite solution for injection; modified sodium hyaluronate gel for injection; medical PVA gel ball-sodium hyaluronate-hydroxypropyl methylcellulose gel; and skin care products. It serves medical aesthetic institutions. The company was incorporated in 2004 and is headquartered in Beijing, China.

Información general

Historia

PróximamenteEsta sección se está completando; vuelve pronto.

Posición en el sector

PróximamenteEsta sección se está completando; vuelve pronto.

Análisis sobre este valor
43/100 Mantener Imeik: New Powder Replaced 71% of the Revenue the Legacy Injectables Lost, But Selling Expense Rose 63% While Sales Fell 6% Imeik makes regulated Class III injectable devices for China's medical-aesthetics market, where hyaluronic-acid solution and gel fillers long produced gross margins above 90% and net margins near 60%. Those two lines fell 20.51% and 23.08% in the first half of 2026 while the new lyophilised PDLLA powder grew to CNY 209.0m and replaced about 71% of the revenue they lost, and selling expense rose 62.89% to CNY 234.8m even as sales fell 6.42%. Rating Hold: at CNY 92.68 the shares sit inside the CNY 90 to 120 acceptable-hold band rather than the CNY 56 to 64 ideal-buy zone, so the conservative CNY 70 to 80 fair value leaves no margin of safety. Imeik Technology Development Co., Ltd.300896 · ShenzhenMedical Devices21 de septiembre de 2026